SEARCH

SEARCH BY CITATION

References

  • 1
    Choo Q-L, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull 1990; 46: 423441.
  • 2
    Miyamura T, Saito I, Katayama T, Kituchi S, Tateda A, Houghton M, Choo Q-L, et al. Detection of antibody against antigen expressed by niolecularly cloned hepatitis C virus DNA: application to diagnosis and blood screening posttransfusion hepatitis. Proc Natl Acad Sci U S A 1990; 87: 893897.
  • 3
    Morb Mortal Wkly Rep 1991; 40: 125.
  • 4
    Alter MJ, Sampliner RE. Hepatitis C: Miles to go before we sleep. N Engl J Med 1989; 321: 15381540.
  • 5
    Alter HJ. Chronic sequences of non-A, non-B hepatitis. In: SeeffLB, LewisJH, eds. Current Perspectives in Hepatology. New York: Plenum, 1989: 8397.
  • 6
    Dienstag JL. Non-A, non-B hepatitis. Recognition, epidemiology and clinical features. Gastroenterology 1983; 85: 439462.
  • 7
    Wejstal R, Lindberg K, Lundin P, Norkrans G. Chronic non-A, non-B hepatitis: a long term follow-up study of 49 patients. Scan J Gastroenterol 1987; 22: 11151121.
  • 8
    Hopf U, Moller B, Kuther D, Stemerociwz R, Lobeck H, Ludtke-Handjery A, Walter E, et al. Long term follow-up of posttransfusion hepatitis and frequency of circulation antibodies to hepatitis C virus. J Hepatol 1990; 10: 6976.
  • 9
    Tremolda R, Casarin C, Alberti A. Long term follow-up of non-A, non-B (type C) posttransfusional hepatitis. J Hepatol 1992; 16: 273281.
  • 10
    Alter HJ, Hoofhagle JH. Non-A, non-B: observations of the first decade. In: VyasGN, DienstagJL, HoofnagleJH, eds. Viral Hepatitis and Liver Disease. Orlando: Grune & Stratton, 1984: 354354.
  • 11
    Hoofhagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, Peters M, Waggoner JG, et al. Treatment of chronic non-A, non-B hepatitis with recombinant alpha interferon. N Engl J Med 1986; 315: 15751578.
  • 12
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized, controlled trial. N Engl J Med 1989; 321: 15011506.
  • 13
    DiBisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double blind, placebo-con trolled trial. N Engl J Med 1989; 321: 15061510.
  • 14
    Marcellin P, Boyer N, Giostra E, Degott C, Courouce AN, Degos F, Coppere H, et al. Recombinant human a interferon in patients with chronic hepatitis non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393397.
  • 15
    Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, et al. A comparison of three doses of interferon alfa-2b regimens for the long term treatment of chronic hepatitis non-A, non-B hepatitis. N Engl J Med 1995; 332: 14571462.
  • 16
    Marcellin P, Pouteau M, Martinot-Pignoux M, Degos F, Duchatelle V, Boyer N, Degott C, et al. Lack of benefits of escalating dosage on interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995; 109: 156165.
  • 17
    Kobayashi Y, Watanabe S, Konishi M, Yoko M, Katehashi R, Kaito M, Kondo M, et al. Quantification and typing of serum hepatitis C RNA in patients with chronic hepatitis C treated with interferon. Hepatology 1993; 18: 13191325.
  • 18
    Castilla A, Camps J, Civira MP, Prieto J. Lymphoblastoid a-interferon for chronic hepatitis C: a randomized controlled study. Amer J Gastroenterology 1993; 88: 233239.
  • 19
    Camps J, Castilla A, Ruiz J, Civira MP, Prieto J. Randomized trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia. J Hepatol 1993; 17: 390396.
  • 20
    Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700706.
  • 21
    Tong MJ, Blatt LM, Resser K, Klein M, Figuero T. Treatment of patients with chronic HCV infection with a novel type-1 interferon, consensus interferon [Abstract]. Hepatology 1993; 18: A150.
  • 22
    Diaz MO, Bohlander S, Allen G. Nomenclature of the human interferon genes. J Interferon Res 1993; 13: 6162.
  • 23
    Fleshner PR, Freilich MI. Adjuvant interferon for anal condyloma. A prospective, randomized trial. Dis Colon Rectum 1994; 37: 12551259.
  • 24
    Liao MJ, Axelrod HR, Kuchler M, Yip YK, Kirkbright E, Testa D. Absence of neutralizing antibodies to interferon in condyloma acuminata and cancer patients treated with natural human leukocyte interferon. J Infect Dis 1992; 165: 757760.
  • 25
    Zhao XX, Hua J, Kuchler M, Testa D, Liao MJ. Absence of neutralizing antibody development in patients treated with interferon alfa-n3. [Abstract]. J Interferon Cytokine Res 1995; 15 (Suppl): 141S.
  • 26
    Shrestha R, McKinley C, Bilir BM, Everson GT. Possible idiopathic thrombocytopenia purpura associated with natural alpha interferon therapy for chronic hepatitis C infection. Am J Gastroenterology 1995; 90: 11461147.
  • 27
    Petka S, Langer JA, Zoom KG, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987; 56: 727777.
  • 28
    Fan SX, Skillman DR, Liao MJ, Testa D, Meltzer MS. Increased efficacy of human natural interferon α(IFN-α n3) versus human recombinant IFN-α 2 for inhibition of HIV-1 replication in primary human monocytes. AIDS Res Hum Retroviruses 1993; 9: 11151122.
  • 29
    Jouet P, Thoraval-Roudot F, Dhumeaux D, Metreau JM. Comparative efficacy of interferon alfa in cirrhotic and non-cirrhotic patients with non-A, non-B C hepatitis. Gastroenterology 1994; 106: 686690.
  • 30
    Reichard O, Faubourg U, Ryden A, Matson L, Norkrans, Sonnenberg A, Wejstal R, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with recombinant interferon α 2b for 60 weeks. Hepatology 1994; 19: 280285.
  • 31
    Gretch DR, Road C, Carither RLL, Wilson RA, Williams B, Carey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlation and clinical implications. Ann Intern Med 1995; 123: 321329.
  • 32
    Castillo I, Bartolome J, Navas S, Gonzales S, Hairier M, Careen V. Virological and long term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994; 19: 13421346.
  • 33
    Gurakar A, Foggily S, Ferric H, Maria N, Balkan M, Van Thiel D, Fried-lander L. Utility of hepatitis C virus determination as an end point for interferon treatment of chronic hepatitis C. Hepatology 1995; 22: 11091112.
  • 34
    Negro F, Bald M, Mondardini A, Landry G, Canad M, Mansion P, Abate ML, et al. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 1994; 107: 479485.
  • 35
    Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. A randomized trial comparing three different regimens of alpha-2a interferon in chronic hepatitis C. Hepatology 1995; 22: 700706.
  • 36
    Picciotto A, Callea F, Varagona G, Bardellini E, Borzone S, De Conca V, Vallarino E, et al. Lymphoblastoid interferon therapy in chronic hepatitis C: biochemical, virological and histological evaluation of two different doses. Liver 1995; 15: 2024.
  • 37
    Hayashi J, Ohmiya M, Kishihara Y, Tani Y, Kinukawa N, Ikematsu H, Seizaburo K. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterology 1994; 89: 21512155.
  • 38
    Saito T, Shinzawa H, Kuboki M, Ishibashi M, Toda H, Okuyama Y, Naka-mura T, et al. A randomized, controlled trial of human lymphoblastoid interferon in patients with compensated cirrhosis. Am J Gastroenterology 1994; 89: 681686.
  • 39
    Terrault N, Wright T. Interferon and hepatitis C. N Engl J Med 1995; 332: 15091511.
  • 40
    Roffi L, Mels CG, Antonelli G, Bellati G, Panizzuti F, Piperno A, Pozzi M, et al. Breakthrough during recombinant interferon alfa therapy in patients with chronic hepatitis C virus infection: prevalence, etiology and management. Hepatology 1995; 21: 645649.
  • 41
    Bonetti P, Diodati G, Casarin C, Scaccaborozzi S, Realdi G, Ruol A, Alberti A. Interferon antibodies in patients with chronic hepatitis C virus infection treated with recombinant interferon alpha-2a. J Hepatol 1994; 20: 416420.
  • 42
    Coonjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 13261329.
  • 43
    Martinot-Peignoux M, Marcellin P, Pouteau C, Castelnau C, Boyer N, Poliquin M, Degott C, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 10501056.